Clinical Toxicities of Histone Deacetylase Inhibitors

By Subramanian Srividya   Bates Susan E.   Wright John J.   Espinoza-Delgado Igor   Piekarz Richard L.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-08 ,pp. : 2751-2767

MDPI

Access to resources Recommend Favorite

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells

By Librizzi Mariangela   Spencer John   Luparello Claudio  

International Journal of Molecular Sciences, Vol. 17, Iss. 8, 2016-07 ,pp. : 1235-1235

MDPI

Access to resources Recommend Favorite

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

By Bishton Mark J.   Johnstone Ricky W.   Dickinson Michael   Harrison Simon   Prince H. Miles  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2674-2688

MDPI

Access to resources Recommend Favorite

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

By Chhabra Saurabh  

Pharmaceuticals, Vol. 10, Iss. 2, 2017-04 ,pp. : 40-40

MDPI

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

By Ellis Leigh   Pili Roberto  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2441-2469

MDPI

Access to resources Recommend Favorite